GSK and Valeant Receive European Authorisation for Trobalt

GlaxoSmithKline GSK and Valeant Pharmaceuticals International, Inc. VRX announced today that the European Commission has granted marketing authorisation for Trobalt (retigabine) as an adjunctive (add-on) treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.